相关实验视频

Updated: Jan 8, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

克罗恩病中使用汇总水平数据进行vedolizumab的药理动力学和药理动力学建模,并将其应用于基于模型的精确剂量定量

Koji Kimura¹, Atsushi Yoshida²

¹Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.

The Journal of pharmacy and pharmacology

|December 16, 2025

概括

基于模型的元分析 (MBMA) 成功构建了一种用于克罗恩病中vedolizumab治疗的药理动力学/药理动力学 (PK/PD) 模型. 这种基于模型的精确剂量 (MIPD) 方法显示了疾病活性的准确预测,即使数据有限.

科学领域:

药理学和临床药学药理学和临床药学
生物统计学和生物信息学
胃肠病学胃肠病学

背景情况:

优化vedolizumab治疗对于管理克罗恩病至关重要.
现有的药理动力学/药理动力学 (PK/PD) 模型通常需要个体患者数据 (IPD).
基于模型的元分析 (MBMA) 提供了使用总结级数据 (SLD) 的替代方案.

研究的目的:

在SLD上开发PK/PD模型使用MBMA对vedolizumab.
评估一种基于模型的精确剂量 (MIPD) 策略,用于克罗恩病的治疗.
评估PK/PD建模与受限制的IPD的可行性.

主要方法:

利用现有的PK分析结果和从PD分析的III期试验中提取的总结级克罗恩病活动指数 (CDAI) 数据.
在NONMEM中采用马尔科夫链蒙特卡洛贝叶斯方法,用于最终的模型装配.
应用经验贝叶斯估计用于MIPD案例研究,使用开发的模型.

主要成果:

最终的PK/PD模型显示了足够的趋同和精度.
在案例研究中,MIPD方法准确地预测了CDAI的时间进程.
使用SLD的MBMA证明可以构建PK/PD模型.

结论:

当IPD无法使用时,通过MBMA在SLD上的PK/PD建模是一种可行的方法.
该MIPD战略显示出强的预测性表现.
建议对IPD进行进一步的研究,以确认MIPD对患者结果的影响.

关键词:

克罗恩氏病是什么克罗恩氏病是什么基于模型的元分析.基于模型的精确剂量定量.我已经看到了Vedolizumab.

更多相关视频

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

相关概念视频

Pharmacokinetic Models: Overview

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...